Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, IBD (inflammatory bowel disease), dyslipidemia) without NAFLD in order to have a clinical phenotypical characterization and the collection of biological specimens. We will collect clinical data, biological samples and imaging results in order to perform future cross-sectional studies and/or longitudinal studies for elucidating pathways of the disease and develop and validate biomarkers for diagnosis, prognosis and monitoring liver disease and comorbidities in order to contribute to precision medicine in this field.

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥18 years - Clinical phenotype of NAFLD (simple steatosis, NASH, metabolic cirrhosis, NAFLD-HCC) based on any of: - Liver biopsy providing histological evidence of NAFLD or, - Biochemical and/or radiological findings consistent with NAFLD - Average alcohol consumption ≤21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years. - Clearance of HCV infection with new DAAs drugs with a SVR (sustained virological response) period \> 6 months - Presence of risk factors for NAFLD (i.e. diabetes, metabolic syndrome, obesity, psoriasis) and absence of fatty liver at US Who Should NOT Join This Trial: - Refusal or inability (lack of capacity) to give willing to sign a consent form. - Average alcohol ingestion \>21/14 units/week (males/females) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years. - History or presence of Type 1 diabetes mellitus. - Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age ≥18 years * Clinical phenotype of NAFLD (simple steatosis, NASH, metabolic cirrhosis, NAFLD-HCC) based on any of: * Liver biopsy providing histological evidence of NAFLD or, * Biochemical and/or radiological findings consistent with NAFLD * Average alcohol consumption ≤21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years. * Clearance of HCV infection with new DAAs drugs with a SVR (sustained virological response) period \> 6 months * Presence of risk factors for NAFLD (i.e. diabetes, metabolic syndrome, obesity, psoriasis) and absence of fatty liver at US Exclusion Criteria: * Refusal or inability (lack of capacity) to give informed consent. * Average alcohol ingestion \>21/14 units/week (males/females) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years. * History or presence of Type 1 diabetes mellitus. * Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.

Locations (1)

Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS
Roma, Rome/lazio/italy, Italy